Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;22(7):291-299.
doi: 10.1007/s11892-022-01469-w. Epub 2022 May 6.

Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes

Molly L Tanenbaum  1 , Persis V Commissariat  2
Affiliations
Review

Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes

Molly L Tanenbaum et al. Curr Diab Rep. 2022 Jul.

Abstract

Purpose of review: Diabetes technology (insulin pumps, continuous glucose monitoring, automated insulin delivery systems) has advanced significantly and provides benefits to the user. This article reviews the current barriers to diabetes device adoption and sustained use, and outlines the known and potential facilitators for increasing and sustaining device adoption.

Recent findings: Barriers to diabetes device adoption continue to exist at the system-, provider-, and individual-level. Known facilitators to promote sustained adoption include consistent insurance coverage, support for providers and clinics, structured education and support for technology users, and device user access to support as needed (e.g., through online resources). Systemic barriers to diabetes device adoption persist while growing evidence demonstrates the increasing benefits of newest devices and systems. There are ongoing efforts to develop evidence-based structured education programs to support device adoption and sustained use.

Keywords: Automated insulin delivery systems; Barriers; Continuous glucose monitoring; Insulin pumps; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors declare no competing interests.

References

    1. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics. 2019;21(2):66–72. - PMC - PubMed
    1. Yeh H-C, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Annals of internal medicine. 2012;157(5):336–47. - PubMed
    1. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S97–S112. - PubMed
    1. Maiorino MI, Signoriello S, Maio A, Chiodini P, Bellastella G, Scappaticcio L, et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. Diabetes Care. 2020;43(5):1146–56. - PubMed
    1. Galindo RJ, Parkin CG, Aleppo G, Carlson AL, Kruger DF, Levy CJ, et al. What’s Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring. Diabetes technology & therapeutics. 2021;23(9):652–60. - PMC - PubMed

Publication types